Aclaris Therapeutics (ACRS)
Develops immunology drug candidates through biologics, kinase inhibitors, and discovery services.
$5.06
vs last close−0.67 (−11.63%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 80.97% | 119.18M shares | |
|---|---|---|---|
| 156 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.18% | 3.21M shares | |
| 13 holders · as of Aug 4, 2026 | |||
| Strategic holders | 7.66% | 11.28M shares | |
| 1 holder · as of Jan 9, 2026 | |||
| Other | ≈ 9.19% | 13.52M shares | |
| remainder | |||
147.20M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
156 holders · 119.18M shares · 30 new positions · 94 increased · 34 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.72M | 8.64% | +5.92M | Aug 14, 2026 |
| BML Capital Management, LLC | 11.98M | 8.14% | −2.28M | Aug 7, 2026 |
| BlackRock, Inc. | 10.04M | 6.82% | +2.63M | Aug 7, 2026 |
| Deep Track Capital, LP | 9.35M | 6.35% | 0 | Aug 14, 2026 |
| Vivo Capital, LLC | 6.69M | 4.55% | +28.0K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 5.82M | 3.95% | +650.4K | Aug 13, 2026 |
| Frazier Life Sciences Management, L.P. | 4.93M | 3.35% | 0 | Aug 14, 2026 |
| Rock Springs Capital Management LP | 4.33M | 2.94% | −142.1K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.90% | 13.95M | 13G | Apr 27, 2026 |
| Biosion, Inc. | 9.40% | 11.28M | 13G | Jan 9, 2026 |
| Vivo Opportunity, LLCincl. Vivo Asia Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman, LLC +1 more | 7.40% | 7.96M | 13G | Nov 21, 2024 |
| Deep Track Capital, LP | 7.00% | 9.35M | 13G | Mar 17, 2026 |
| RA Capital Management, L.P. | 6.30% | 7.63M | 13G | Apr 7, 2026 |
| BlackRock, Inc. | 6.20% | 6.70M | 13G | Jan 21, 2026 |
| Frazier Life Sciences Public Fund, L.P. | 5.40% | 7.88M | 13G | Sep 21, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 23, 2026 | Braden Michael Leonard10 percent owner | Sale | 300,000 | $4.53 | 13,950,000 |
House and Senate disclosures
Not reported.